If you entered a Chemist Warehouse store on a Saturday morning in any Australian suburb, you would see the same scene that has been happening for years: towers of cheap vitamin bottles, fluorescent lighting, parents waiting in line for prescriptions, and the gentle chaos of one of the nation’s most persistently prosperous retail establishments. The corporate machinery that powers the brand is what you wouldn’t see, and for the last year or so, that machinery has been going by the moniker Sigma Healthcare. Since the closing of the merger in February 2025, which transformed a solid mid-cap drug wholesaler into a about AU$33 billion ASX heavyweight, the share price has been acting in an oddly unimpressive manner.
At the lower end of its 52-week range of AU$2.58 to AU$3.28, Sigma is presently trading at about AU$2.86. Depending on the start date you choose, the stock has practically been unchanged during the last 12 months. For a company that, on paper, has closed the most significant corporate merger in Australian pharmacy retail in a generation, that is an odd location. Almost overnight, the transaction increased Sigma’s market capitalization from a few billion dollars to the AU$30 billion area. The shares momentarily surpassed $3 before the market subtly returned the majority of the post-deal excitement.
Every Sigma investor is currently attempting to determine whether the present delay is due to disappointment or digestion. Digestion has a plausible justification. It takes time to integrate mergers of this magnitude, especially those that combine a privately held, founder-led retail enterprise with a public wholesaler. Reconciliation is required for inventory systems, store rollouts, marketing expenditures, and franchise agreements with the larger Sigma-served drugstore network. The trailing twelve-month P/E ratio is above 55, indicating that substantial profits growth that hasn’t yet materialized in the reported figures is still being priced in by the market. The wager is whether that growth will occur during the next two earnings cycles.
The same image can alternatively be interpreted in a less optimistic way that is more difficult to ignore. Community pharmacies in Australia are evolving more quickly than the public-market story indicates. The Pharmaceutical Benefits Scheme continues to change in ways that reduce prescription drug profit margins. The Chemist Warehouse value proposition is being threatened by discount rivals, internet competitors, and health services that are located next to supermarkets. Contract negotiations with large drugstore chains put strain on Sigma’s wholesale business, the dull base behind the glamorous retail layer. These problems are not existential. They are all heavy.
It’s remarkable how little the Australian market as a whole seems to understand about post-merger Sigma. Major brokers’ coverage has been inconsistent. The average twelve-month analyst target is approximately AU$3.31, suggesting a slight but not significant increase. Chemist Warehouse is one of the top retail companies in the nation, according to Morningstar, which has been writing positively about the underlying company quality. However, the consensus rating is Buy without being very enthusiastic, which indicates that experts are unable to find a reason to sell but are also unable to provide a clear explanation for why the stock should rise.
The cultural aspect of this narrative, which frequently gets overlooked in financial coverage, is difficult to overlook. The founders of Chemist Warehouse, Jack Gance and Mario Verrocchi, spent decades creating one of Australia’s most subtly influential retail brands by being a little more aggressive when it came to pricing, a little more flexible when it came to store layout, and a little more disciplined when it came to supplier negotiations than anyone gave them credit for. In a sense, their succession plan was the merger with Sigma. The market is still attempting to determine whether the founder’s enthusiasm transfers into a publicly traded corporate structure or if something is lost in the process. Both results are common in retail history.
The experience has been mostly positive for shareholders who held Sigma during the transaction. Not thrilling, not disastrous. Over the past year, the stock has underperformed the ASX All Ordinaries Index by several percentage points, and the dividend is still little at roughly 1.3% trailing yield with no clarity on the next pay date. The full-year results, which will give investors their best chance to see how the combined company truly makes money, are thought to be the next big driver. Until then, Sigma remains where it has been for months. A larger business than it was, trading at nearly the same price while it waited for the market to decide.
